Cystic Fibrosis–related Diabetes: A First Canadian Clinical Practice Guideline
Adèle Coriati, Kj Potter, Julie Gilmour, Grace Y. Lam, Carly Nichols, Larry C. Lands, M.A. Doyle, Valérie Boudreau, Laure Alexandre‐Heymann, M. McKinney, Diana Sherifali, Peter Senior, REMI RABASA-LHORET, Laure Alexandre-Heymann, Glenda N. Bendiak, Christelle Bergeron, Lara Bilodeau, Mark Chilvers, Jane Corbeil, Marie-Hélène Denis, Gary J. Galante, Kate Gent, Sabrina Gill, Lori Fairservice, Mark D. Inman, Amanda Jober, Tamizan Kherani, Annick Lavoie, Paola Luca, Lisa Mannik, Seth D. Marks, Martha L. McKinney, John Michael Nicholson, Patricia Olivier, Vicky Parkins, Meghan Pohl, Agnès Räkel, Megan Racey, Rhiza Regalado Lam Chew Tun, Ronalee Robert, Diana Sherifali, Tamara Spaic, Laura Stewart, Amy Washington, Zofia Zysman-Colman
Abstract
CF is an autosomal recessive disease due to dysfunction or absence of the CF transmembrane conductance regulator (CFTR) channel. CF affects >4,000 Canadians, and has a major effect on the lungs, the gastrointestinal system, quality of life, and lifespan [1]. Innovations in nutrition, physiotherapy, and respiratory medicine have revolutionized CF care and increased life expectancy. The current median survival is 59.9 years [1]. New therapies (highly effective modulators) are expected to further improve lifespan.